TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07456033: The MODIFY Study: A Phase 3b/4 Randomized, Double-blind, Placebo-controlled, Multi-centre Study Evaluating the Impact of Early Intervention With Depemokimab on Exacerbation Rate, Clinical Remission, Lung Function Decline

Sponsor: GlaxoSmithKline · Phase: PHASE3 · Area: IMMUNOLOGY · Target Enrollment: 456 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$7,201,530

Rescue Site Savings

+$4,752,030

Unlock Full NCT07456033 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07456033 Rescue Dossier →